FIELD: medicine.
SUBSTANCE: claimed invention relates to immunology and biotechnology. Claimed are: a pharmaceutical composition and a method, based on an introduction to a patient of a therapeutically efficient amount of an antibody against CD200, which contains G2/G4 constant region, for treatment of the patient with malignant neoplasm, containing CD200 positive malignant cells. The said antibody against CD200 inhibits interaction between CD200 and CD200R.
EFFECT: application of the invention ensures better inhibition of the tumour growth with reduced effector function in comparison with application of the antibody, containing G1constant region, which can be applied in medicine.
24 cl, 29 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF DESTROYING CELLS USING EFFECTOR FUNCTIONS OF ANTI-EphA4 ANTIBODIES | 2007 |
|
RU2429246C2 |
| ANTIBODIES AGAINST PD-1 AND THEIR USE | 2018 |
|
RU2788616C2 |
| ANTIBODIES TO PROGRAMMED CELL DEATH PROTEIN 1 | 2018 |
|
RU2812915C2 |
| METHODS OF TREATING CANCER USING ANTAGONISTS BINDING TO PD-1 AXIS AND TIGIT INHIBITORS | 2014 |
|
RU2702108C2 |
| IMPROVED METHODS OF TREATING VASCULARISED MALIGNANT TUMORS | 2015 |
|
RU2692248C2 |
| TREATMENT OF CANCER, USING ANTIBODY TO SEMAPHORIN 4D IN COMBINATION WITH EPIGENETIC MODULATING AGENT | 2018 |
|
RU2783535C2 |
| METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS | 2014 |
|
RU2825390C2 |
| LIGAND GITR AND MOLECULES AND ANTIBODIES BOUND WITH LIGAND GITR, AND VERSIONS OF THEIR APPLICATION | 2004 |
|
RU2369636C2 |
| ANTI-INTEGRIN ALPHA-2 ANTIBODIES AND USING THEM | 2011 |
|
RU2545401C2 |
| ANTIBODIES RECOGNISING CARBOHYDRATE CONTAINING EPITOPE ON CD-43 AND CEA EXPRESSED ON CANCER CELLS, AND METHODS OF USING SUCH | 2007 |
|
RU2461572C2 |
